Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound of the formula I:
wherein:
R 1 and R 2 are different, independent groups and are selected from the group consisting of OR 3 and N(R 3′ )(R 3″ ); or
R 1 and R 2 are different, are connected through a single bond, and are selected from the group consisting of O and NR 3 ;
R 3 , R 3′ , and R 3″ are independently selected from the group consisting of H, C 1 to C 6 alkyl, C 1 to C 6 substituted alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
R 4 and R 4′ are:
(a) independently selected from the group consisting of H, OH, O(C 1 to C 6 alkyl), O(substituted C 1 to C 6 alkyl), O(acyl), O(aryl), O(substituted aryl), and halogen; or
(b) taken together to form a double bond to O;
R 5 , R 6 , and R 7 are independently selected from the group consisting of H, OH, and OCH 3 ;
R 8 and R 9 are connected through a double bond and are CH;
R 15 is selected from the group consisting of C═O, CHOH, and CH 2 ;
n is 1 or 2;
wherein the acyl group is HC(O)— or a —C(O)R′″— group, wherein R′″ is selected from C 1 to C 6 alkyl, substituted alkyl, and alkoxy;
wherein the heteroaryl group is a monocyclic, aromatic 4- to 7-membered ring having one to four heteroatoms independently selected from N, S and O;
wherein the aryl group is an aromatic system of 6-20 carbon atoms in a single or multiple ring fused or linked ring system wherein at least one part of the fused or linked rings forms the conjugated system;
wherein the substituents for the substituted alkyl, aryl, heteroaryl, or acyl are one or more substituents independently selected from halogen, CN, OH, NO 2 , amino, aryl, a heterocyclic ring consisting of a monocyclic, saturated, partially unsaturated, or wholly unsaturated 4- to 7-membered ring having 1 to 4 heteroatoms independently selected from N, S, O, alkoxy, aryloxy, alkylcarbonyl, alkylcarboxy, and arylthio; or a pharmaceutically acceptable salt thereof.
2. The composition according to claim 1 , wherein said R 1 and R 2 are connected through a single bond.
3. The composition according to claim 1 , wherein R 1 is O, R 2 is NR 3 .
4. The composition according to claim 1 , wherein R 1 is OR 3 and R 2 is N(R 3′ )(NR 3″ ).
5. The composition according to claim 1 , wherein R 3 , R 3′ or R 3″ is an aryl or substituted aryl.
6. The composition according to claim 5 , wherein said substituted aryl is a substituted benzene ring.
7. The composition according to claim 6 , wherein said aryl or substituted aryl is of the structure:
wherein:
R 10 , R 11 , R 12 , R 13 , and R 14 are independently selected from the group consisting of H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halogen, acyl, OH, O(alkyl), O(substituted alkyl), O(aryl), O(substituted aryl), O(acyl), NH 2 , NH(alkyl), NH(substituted alkyl), NH(aryl), NH(substituted aryl), and NH(acyl).
8. The composition according to claim 1 , wherein R 4 or R 4′ is OH.
9. The composition according to claim 1 , wherein R 4 or R 4′ is O(acyl).
10. The composition according to claim 9 , wherein said acyl is:
11. The composition according to claim 1 , wherein R 5 , R 6 , and R 7 are OCH 3 .
12. The composition according to claim 1 , wherein n is 2.
13. The composition according to claim 1 , wherein R 15 is C═O.
14. The composition according to claim 1 , wherein R 1 is OR 3 ; R 2 is N(R 3′ )(R 3″ ); R 3 is H; R 3′ is H; R 3″ is phenyl; R 4 is OH; R 5 -R 7 are OCH 3 .
15. The composition according to claim 1 , wherein R 1 and R 2 are connected through a single bond; R 1 is O; R 2 is NR 3 ; R 3 is phenyl; R 4 is OH; R 5 -R 7 are OCH 3 .
16. The composition according to claim 1 , wherein R 1 and R 2 are connected through a single bond; R 1 is O; R 2 is NR 3 ; R 4 is OH; R 5 -R 7 are OCH 3 ; and R 3 is
17. The composition according to claim 1 , wherein R 1 and R 2 are connected through a single bond; R 1 is O; R 2 is NR 3 ; R 4 is OH; R 5 -R 7 are OCH 3 ; and R 3 is
18. The composition according to claim 1 , wherein R 1 and R 2 are connected through a single bond; R 1 is O; R 2 is NR 3 ; R 3 is phenyl; R 5 -R 7 are OCH 3 ; and R 4 is